Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination.
Ontology highlight
ABSTRACT: Tumor specific antigens (TSA) provide an opportunity to mobilize therapeutic immune responses against cancer. To evade such responses, tumor development in immunocompetent hosts is accompanied by acquisition of both active and passive mechanisms of immune suppression, including recruitment of CD4+FoxP3+ regulatory T cells (Treg). Thymic derived Treg (nTreg) may recognize self-antigens in the tumor microenvironment, while peripherally induced Treg (iTreg) may preferentially recognize the same TSA which provide an opportunity for therapeutic immunity from peripheral T cells. In this study we provide a systematic analysis of nTreg and iTreg accumulation in the tumor microenvironment (TME) at the cellular level. iTreg accumulation to the TME was influenced by the abundance of a known TSA, and
SUBMITTER: Schreiber TH
PROVIDER: S-EPMC3429568 | biostudies-literature | 2012 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA